IDP-023

· Indapta Therapeutics, INC.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IDP-023, covering 2025-06-03 to 2025-06-03. Get the full timeline:

Most recent: Clinical Trial Update: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers [Phase 1, Phase 2]

See pricing